Richard T. Kenney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard T. Kenney has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Albert A. Gam
Laboratory of Parasitic Biology and Biochemistry, Center for Biologies Evaluation and Research, Food and Drug Administration, Bethesda, Maryland
2 shared publicationsDavid L. Sacks
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Health , Bethesda, MD 20892
2 shared publicationsAlbert A Gam
Laboratory of Parasitic Biology and Biochemistry, Food and Drug Administration , Bethesda, MD 20852
1 shared publicationHenry W. Murray
1 shared publicationJoseph P. Sypek
Preclinical Research and Development, Genetics Institute , Andover, MA 01810
1 shared publicationKamela Evans-Davis
Division of Veterinary Medicine, Center for Biologics Evaluation and Research, Food and Drug Administration , Bethesda, MD 20852
1 shared publication
Latest Publications
- Open Access
- 1 March 2000
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 181 (3) , 1121-1128
Inhibition of Interferon‐γ Signaling byLeishmania donovani
Leishmania infection causes marked down-regulation of interferon (IFN)-γ-induced gene activity in macrophages, but the mechanism of the blockade has
- 1 March 2000
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 181 (3) , 1121-1128
Open AccessInhibition of Interferon‐γ Signaling byLeishmania donovani
Leishmania infection causes marked down-regulation of interferon (IFN)-γ-induced gene activity in macrophages, but the mechanism of the blockade has
- Open Access
- 15 October 1999
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 163 (8) , 4481-4488
Protective Immunity Using Recombinant Human IL-12 and Alum as Adjuvants in a Primate Model of Cutaneous Leishmaniasis
Protection from cutaneous leishmaniasis, a chronic ulcerating skin lesion affecting millions, has been achieved historically using live virulent preparations of the parasite. Killed or recombinant Ags that could be safer as vaccines generally require an adjuvant for induction of a strong Th1 response in murine models. Murine rIL-12 as an adjuvant with soluble Leishmania Ag has been shown to protect susceptible mice. We used 48 rhesus macaques to assess the safety, immunogenicity, and efficacy of a vaccine combining heat-killed Leishmania amazonensis with human rIL-12 (rhIL-12) and alum (aluminum hydroxide gel) as adjuvants. The single s.c. vaccination was found to be safe and immunogenic, although a small transient s.c. nodule developed at the site. Groups receiving rhIL-12 had an augmented in vitro Ag-specific IFN-γ response after vaccination, as well as increased production of IgG. No increase in IL-4 or IL-10 was found in cell culture supernatants from either control or experimental groups. Delayed hypersensitivity reactions were not predictive of protection. Intradermal forehead challenge infection with 107 metacyclic L. amazonensis promastigotes at 4 wk demonstrated protective immunity in all 12 monkeys receiving 2 μg rhIL-12 with alum and Ag. Partial efficacy was seen with lower doses of rhIL-12 and in groups lacking either adjuvant. Thus, a single dose vaccine with killed Ag using rhIL-12 and alum as adjuvants was safe and fully effective in this primate model of cutaneous leishmaniasis. This study extends the murine data to primates, and provides a basis for further human trials.
- 15 October 1999
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 163 (8) , 4481-4488
Open AccessProtective Immunity Using Recombinant Human IL-12 and Alum as Adjuvants in a Primate Model of Cutaneous Leishmaniasis
Protection from cutaneous leishmaniasis, a chronic ulcerating skin lesion affecting millions, has been achieved historically using live virulent preparations of the parasite. Killed or recombinant Ags that could be safer as vaccines generally require an adjuvant for induction of a strong Th1 response in murine models. Murine rIL-12 as an adjuvant with soluble Leishmania Ag has been shown to protect susceptible mice. We used 48 rhesus macaques to assess the safety, immunogenicity, and efficacy of a vaccine combining heat-killed Leishmania amazonensis with human rIL-12 (rhIL-12) and alum (aluminum hydroxide gel) as adjuvants. The single s.c. vaccination was found to be safe and immunogenic, although a small transient s.c. nodule developed at the site. Groups receiving rhIL-12 had an augmented in vitro Ag-specific IFN-γ response after vaccination, as well as increased production of IgG. No increase in IL-4 or IL-10 was found in cell culture supernatants from either control or experimental groups. Delayed hypersensitivity reactions were not predictive of protection. Intradermal forehead challenge infection with 107 metacyclic L. amazonensis promastigotes at 4 wk demonstrated protective immunity in all 12 monkeys receiving 2 μg rhIL-12 with alum and Ag. Partial efficacy was seen with lower doses of rhIL-12 and in groups lacking either adjuvant. Thus, a single dose vaccine with killed Ag using rhIL-12 and alum as adjuvants was safe and fully effective in this primate model of cutaneous leishmaniasis. This study extends the murine data to primates, and provides a basis for further human trials.
- Open Access
- 1 March 1998
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 177 (3) , 815-819
Splenic Cytokine Responses in Indian Kala‐Azar before and after Treatment
Cytokine mRNA levels were measured in serial splenic aspirates from 27 patients with visceral leishmaniasis during monotherapy with interferon-γ (IFN
- 1 March 1998
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 177 (3) , 815-819
Open AccessSplenic Cytokine Responses in Indian Kala‐Azar before and after Treatment
Cytokine mRNA levels were measured in serial splenic aspirates from 27 patients with visceral leishmaniasis during monotherapy with interferon-γ (IFN